Edition:
India

Sunesis Pharmaceuticals Inc (SNSS.OQ)

SNSS.OQ on NASDAQ Stock Exchange Capital Market

2.48USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$2.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
24,060
52-wk High
$4.44
52-wk Low
$1.84

Chart for

About

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $56.67
Shares Outstanding(Mil.): 23.51
Dividend: --
Yield (%): --

Financials

BRIEF-Sunesis Pharmaceuticals Inc - Daniel Swisher Resigns As CEO Effective End Of 2017

* SUNESIS PHARMACEUTICALS INC - DANIEL SWISHER RESIGNS AS CEO EFFECTIVE END OF 2017

05 Dec 2017

BRIEF-Sunesis Pharmaceuticals Appoints William Quinn As CFO

* SUNESIS PHARMACEUTICALS APPOINTS WILLIAM QUINN AS CHIEF FINANCIAL OFFICER AND SENIOR VICE PRESIDENT, FINANCE AND CORPORATE DEVELOPMENT

30 Nov 2017

BRIEF-RA Capital Management reports 10.4 pct passive stake in Sunesis Pharmaceuticals as of Oct 25

* RA Capital Management reports 10.4 percent passive stake in Sunesis Pharmaceuticals as of October 25 – SEC Filing‍​ Source text: [http://bit.ly/2yZzSQ5] Further company coverage:

14 Nov 2017

BRIEF-Sunesis Pharmaceuticals Inc Q3 loss per share ‍$0.43​

* Sunesis Pharmaceuticals reports third quarter 2017 financial results and recent highlights

02 Nov 2017

BRIEF-Sunesis announces pricing of $20 million offering of securities

* Sunesis announces pricing of $20 million offering of securities

25 Oct 2017

BRIEF-Sunesis Pharmaceuticals announces proposed public offering of common stock, preferred stock and warrants

* Sunesis announces proposed public offering of common stock, preferred stock and warrants

25 Oct 2017

BRIEF-Sunesis Pharmaceuticals reports second quarter results

* Sunesis Pharmaceuticals reports second quarter 2017 financial results and recent highlights

27 Jul 2017

BRIEF-Balyasny Asset Management reports 9.32 pct passive stake in Sunesis Pharmaceuticals

* Balyasny Asset Management reports a 9.32 percent passive stake in Sunesis Pharmaceuticals Inc as of June 23, 2017 - SEC filing Source text: (http://bit.ly/2tRWgIv) Further company coverage:

05 Jul 2017

BRIEF-Sunesis Pharmaceuticals amends loan agreement

* Sunesis Pharmaceuticals Inc - on June 30, 2017, co entered into an amendment, or amendment, to loan and security agreement dated march 31, 2016

01 Jul 2017

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥6,673 +140.00
Johnson & Johnson (JNJ.N) $140.59 +0.58
Novartis AG (NOVN.S) CHF83.10 --
Pfizer Inc. (PFE.N) $35.74 +0.24
Merck & Co., Inc. (MRK.N) $55.57 +0.80
Celgene Corporation (CELG.OQ) $106.09 +3.36

Earnings vs. Estimates